CSPs to cost Canada C$392 million a year

Two-year certificates of supplementary protection (CSPs) will cost Canadians C$392 million (US$302 million) per year, according to an analysis conducted by the office of the country’s Parliamentary Budget Officer (PBO). CSPs were introduced in Canada under the terms of the country’s Comprehensive Economic and Trade Agreement (CETA) with the European Union (EU).

Two-year certificates of supplementary protection (CSPs) will cost Canadians C$392 million (US$302 million) per year, according to an analysis conducted by the office of the country’s Parliamentary Budget Officer (PBO). CSPs were introduced in Canada under the terms of the country’s Comprehensive Economic and Trade Agreement (CETA) with the European Union (EU).

Using Iqvia data, the report assesses the increased cost to Canadians had CSP patent-term restoration periods been in place in...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin